Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment-Reference-Cited by-同舟云学术

Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment

Published:2016-04-22 Issue:9 Volume:61 Page:2465-2476
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Lin Xiao-Jun,Lao Xiang-Ming,Shi Ming,Li Sheng-Ping

Funder

The work was partly supported by the foundation for the outstanding young scholar award (Dr. Xiang-Ming Lao) from Sun Yat-sen University Cancer Center

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10620-016-4167-5.pdf

Reference96 articles.

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.

2. Wei KR, Yu X, Zheng RS, et al. Incidence and mortality of liver cancer in China, 2010. Chin J Cancer. 2014;33:388–394.

3. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2:1129–1133.

4. Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141:1240–1248. (1248 e1241–1248 e1242).

5. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–1801.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma;BMC Cancer;2023-03-13

2. Comparison of the Efficacy and Safety of Transarterial Chemoembolization Plus Microwave Ablation versus Surgical Resection in Patients with Solitary Large Hepatocellular Carcinoma: A Propensity Score-Matched Analysis;Journal of Hepatocellular Carcinoma;2022-12

3. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression;Cancer Management and Research;2021-05

4. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis;Cancer Immunology, Immunotherapy;2021-04-03

5. Association of Hepatitis B Virus DNA Level and Follow-up Interval With Hepatocellular Carcinoma Recurrence;JAMA Network Open;2020-04-27